Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

(2013) T. Heise et al.   DIABETES OBESITY & METABOLISM

Comment on: Turban et al. Optimal Elevation of  -Cell 11 -Hydroxysteroid Dehydrogenase Type 1 Is a Compensatory Mechanism That Prevents High-Fat Diet-Induced  -Cell Failure. Diabetes 2012;61:642-652

(2012) J.-L. Liu et al.   DIABETES

Association Between Glycosylated Hemoglobin and Intentional Weight Loss in Overweight and Obese Patients With Type 2 Diabetes Mellitus

(2012) Ghanshyam Palamaner Subash Shantha et al.   DIABETES EDUCATOR

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)

(2012) Ishan Hirji et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Blood pressure and risk of cardiovascular diseases in type 2 diabetes

(2012) Jan Cederholm et al.   JOURNAL OF HYPERTENSION

Standards of Medical Care in Diabetes--2012

(2011)   DIABETES CARE

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

(2011) R. R. Wing et al.   DIABETES CARE

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

(2011) R. A. DeFronzo et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs

(2011) C. Ll. Morgan et al.   DIABETES OBESITY & METABOLISM

The Parathyroid Glands: What the Endocrine Surgeon Should Know

(2011) Nancy Perrier   Endocrine Practice

Glucose handling by the kidney

(2011) Amanda Mather et al.   KIDNEY INTERNATIONAL

Renal glucose reabsorption inhibitors to treat diabetes

(2011) Clifford J. Bailey   TRENDS IN PHARMACOLOGICAL SCIENCES

Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes

(2010) Olivia J. Phung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sulphonyurea as a cause of severe hypoglycaemia in the community

(2010) Jen M. Ng et al.   Primary Care Diabetes

Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life

(2009) Michael F. Pollack et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents

(2009) A. B. Hauber et al.   DIABETIC MEDICINE

Weight Change in Diabetes and Glycemic and Blood Pressure Control

(2008) A. C. Feldstein et al.   DIABETES CARE

Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia: A nested case-control analysis

(2008) M. Bodmer et al.   DIABETES CARE

Uric Acid and Cardiovascular Risk

(2008) Daniel I. Feig et al.   NEW ENGLAND JOURNAL OF MEDICINE